http://phys.org/ en-us Phys.org internet news portal provides the latest news on science including: Physics, Nanotechnology, Life Sciences, Space Science, Earth Science, Environment, Health and Medicine. HP today announced an innovative drug research application for its inkjet technology that enables pharmaceutical companies to more efficiently develop better drugs through vastly more precise dispensing of dosages. http://phys.org/news219070691.html Medicine & Health Fri, 11 Mar 2011 12:58:25 EST news219070691 In a previous study, rheumatoid arthritis (RA) patients who failed to respond to methotrexate were shown to experience positive results with fostamatinib disodium (R788), an oral spleen tyrosine kinase (Syk) inhibitor that is thought to block immune cell signaling involved with bone and cartilage destruction. In the current study, RA patients who failed to respond to biologic agents were studied. In contrast to the prior study, however, fostamatinib was not effective in this group of patients, although the drug did appear to be safe. Results of this phase II trial are published in the February issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR). http://phys.org/news215346663.html Medicine & Health Thu, 27 Jan 2011 10:31:52 EST news215346663 A study conducted at Copenhagen University Hospital showed that treatment of rheumatoid arthritis (RA) with disease modifying antirheumatic drugs (DMARDs), glucocorticoids, biologic agents, or a combination of agents significantly reduced radiographic evidence of joint destruction, with a relative effect of 48%󈞴% as compared with placebo. A direct comparison between the combination of a biologic agent plus methotrexate and the combination of 2 DMARDs plus initial glucocorticoids revealed no difference. Study findings are published in the October issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology. http://phys.org/news204894060.html Medicine & Health Tue, 28 Sep 2010 12:01:14 EST news204894060 Colorectal cancer (CRC) is the second leading cause of cancer-related death in the Western world. Fortunately physicians today have an abundance of drug therapies available to improve survival length for more advanced cancer patients. Now the discovery of genetic biomarkers relevant to CRC means that targeted personalised medication is increasingly common. http://phys.org/news170073793.html Medicine & Health Fri, 21 Aug 2009 12:10:01 EST news170073793